Company Description:

Bionomics is a biopharmaceutical company dedicated creating new therapies that serve large unmet needs in cancer and diseases of the central nervous system (CNS) such as anxiety, depression and Alzheimer's. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. Bionomics is based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France.


Recent Developments:

- BNC105 ovarian cancer Phase I trial and renal cancer phase II trial completed enrolment
- BNC101 cancer stem cell (CSC) antibody pre-IND filing,
- US$172M pain partnership with Merck & Co
- Advancing partnership discussions on BNC375 and Kv1.3 drug candidate BNC164
- Partnership with CRC-Cancer Therapeutics yields potential new cancer drug candidate for the treatment of melanoma

Intellectual Property/Products/Product Development Programs: (non-resources companies only)

Bionomics has a broad and deep portfolio of drug candidates;

- BNC105, solid tumour targeting agent
- BNC210 (IW-2143) targeting anxiety and depression (partnered with Ironwood Pharmaceuticals)
- BNC101 and BNC102 Cancer Stem Cell (CSC) targeting antibodies
- BNC375 targeting Alzheimer's and Parkinson's Disease
- BNC164 targeting Psoriasis

Bionomics’ discovery and development activities are driven by its four proprietary technology platforms:

- Angene®, MultiCore®, ionX® and CSC Rx Discovery Platform™

Bionomics has over 40 patents or patents pending for novel drugs in development and technology platforms.

Significant Contractual Arrangements:
• US$172M pain partnership with Merck & Co
• Ironwood Pharmaceutical / Bionomics License Agreement to further develop and Commercialise BNC210: up to US$345 million in milestone payments plus royalties on product sales.
• Collaboration Partnership with CRC – development of new drug candidate for melanoma

Future Outlook:

The next 12 months will see a number of important near term valuation catalysts for Bionomics shareholders, including:

• BNC105 clinical trial program: Results from both the Renal Phase II and the Ovarian Phase I trials in Q1
• BNC101 IND Submission
• Partnering of our drug candidates, with negotiations ongoing on BNC375 and BNC164

Presentation by:

Dr Deborah Rathjen
CEO & Managing Director

A seasoned biotech executive of over 20 years, Dr Deborah Rathjen joined Bionomics in June 2000 from Peptech Limited, where she was Manager of Business Development and Licensing. Dr Rathjen was a co-inventor of Peptech’s TNF technology and leader of the company’s successful defence of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. This success saw the company grow from a A$17m market capitalisation to a A$500m market capitalisation. Dr Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, and business development and licensing. Since 2008 Dr Rathjen has been Chairperson of the AusBiotech Board, and is a former member of the Prime Minister’s Science Engineering and Innovation Council. Dr Rathjen has received a number of awards including the AusBiotech President’s Medal for her significant contribution to the Australian biotechnology industry, in 2006 she received a Distinguished Alumni Award from Flinders University, in 2009 the BioSingapore Asia Pacific Woman Entrepreneur of the Year, in 2010 the Bio Innovation SA Industry Leader Award, and in 2013 BioSpectrum Asia-Pacific Person of the Year.

Contact Details:

Correspondence Address: 31 Dalgleish Street, Thebarton, South Australia 5031
Phone Number: +61 (0)8 8354 6101
Email Address: drathjen@bionomics.com.au
Website: www.bionomics.com.au

This profile is provided by the presenting company; ASX takes no responsibility for the information included. Participation in this event should not be taken as an endorsement by ASX of the company.